Antibody/Peptide Discovery at Creative Biolabs Extended to Cover HIV & Hepatitis Virus
Creative Biolabs announces antibody and peptide discovery services for HIV and hepatitis virus to facilitate clients’ valuable viral disease research and project development.
New York, United States – October 22, 2021 /MarketersMEDIA/ —
Viruses have been humanity’s constant companions, as for a long time, people have been fighting against a vast range of viral diseases like Zika, Ebola, HIV, or SARS-CoV-2 to name but a few. The complicated life cycle and rapid genetic mutations of viruses demand the continuous development of novel medicines with high efficacy and safety profiles. Antibodies and peptides provide a promising outlook as tools to combat the spread and re-emergence of viral infections.
To facilitate viral disease research and project development, Creative Biolabs employs different immunization strategies for anti-virus biomolecular discovery, dedicated to promoting antibody and peptide discovery for viral diseases to support diagnostic and therapeutic purposes.
Research has proved that broadly neutralizing antibodies can target specific vulnerable sites on the HIV-1 envelope, mediate neutralization, and target infected cells for elimination. The scientist team at Creative Biolabs has accumulated extensive experience in broadly neutralizing antibodies (bNAbs) discovery service targeting human immunodeficiency virus type 1 (HIV-1), covering the most potential targets of BNAbs, such as CD4 binding site (CD4bs), membrane proximal external region (MPER), V2 site, N332 supersite, gp120–gp41 interface.
In a context where the scalability of bNAb is limited by the economic cost of production and the mandatory requirements for parenteral administration, peptides are considered as possible HIV-1 treatment. The anti-HIV-1 peptide discovery service at Creative Biolabs can help develop ideal peptides with high specificity and affinity towards their molecular targets.
With the established AntInfect™ Platform covering a wide range of techniques for anti-infective antibody/peptide discovery, CRISPR screening, siRNA screening, and small molecule drug discovery, Creative Biolabs offers hepatitis virus-targeted antibodies and peptides discovery service.
This service can be customized for the most common types of hepatitis: hepatitis A, hepatitis B, hepatitis C, hepatitis D, and hepatitis E. In addition, scientists at Creative Biolabs are skillful at facilitating clients’ hepatitis virus drug discovery services with deep insight into the most researched targets for hepatitis antibody or vaccine development, including VP structural protein, surface antigen, core protein, envelope protein, etc.
Furthermore, Creative Biolabs also provides antibody and antimicrobial peptide discovery for other viruses, including but not limited to SARS-CoV-2, Ebola virus, and Influenza virus. Further information can be found on https://www.creative-biolabs.com/antinfect/.
About Creative Biolabs
As a leading custom service provider in antibody development and engineering, Creative Biolabs has established cutting-edge technology to support functional biomolecules development for infectious diseases. The service portfolio is comprised of anti-infective biomolecules discovery, CRISPR screening, siRNA screening, and small molecule drug discovery.
Release ID: 89050121